+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Analgesics Market - Global Forecast 2026-2032- Product Image
Analgesics Market - Global Forecast 2026-2032- Product Image
Sale

Analgesics Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5264364
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Analgesics Market is projected to reach USD 47.99 Billion in 2026. It is expected to continue growing at a CAGR of 6.91%, reaching USD 71.82 Billion by 2032.

Analgesics remain one of the most essential pharmaceutical categories because pain is among the leading reasons people seek medical care and a major driver of disability, productivity loss, and healthcare utilization. The category spans non-opioid analgesics such as acetaminophen/paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, topical pain relievers, fixed-dose combinations, and adjuvant therapies used in neuropathic, inflammatory, cancer-related, and postoperative pain.

Demand is supported by population aging, the rising prevalence of musculoskeletal disorders, cancer-related pain, postsurgical recovery needs, and greater consumer reliance on over-the-counter pain management. At the same time, regulatory agencies, including the U.S. FDA and European Medicines Agency, continue to shape the category through opioid risk mitigation, pharmacovigilance requirements, acetaminophen hepatotoxicity warnings, and safety communications on NSAID cardiovascular, renal, and gastrointestinal risks.

Transformative Shifts in the Analgesics Landscape

The analgesics landscape is being reshaped by the shift from volume-led prescribing to evidence-based, risk-stratified pain management. Health systems are prioritizing multimodal pain care, opioid-sparing protocols, abuse-deterrent formulations, prescription drug monitoring, and stronger patient education to balance effective relief with safety.

Another major shift is the expansion of consumer-centric pain management. Digital pharmacies, e-commerce OTC channels, telehealth consultations, and private-label analgesics are changing how patients access common pain medications. Meanwhile, manufacturers are investing in differentiated delivery formats, including topical gels, transdermal systems, extended-release products, unit-dose packaging, and combination therapies that improve convenience, adherence, dosing accuracy, and targeted pain relief.

Cumulative Impact of Artificial Intelligence on Analgesics

Artificial intelligence is having a cumulative impact across the analgesics value chain, from target discovery and molecule screening to real-world safety monitoring. AI-enabled platforms can analyze genomic, proteomic, clinical, imaging, and claims data to identify pain pathways, stratify patients, and support faster development of non-opioid candidates for inflammatory, neuropathic, and postoperative pain.

In commercial and clinical settings, AI is improving supply planning, adverse-event signal detection, medication adherence programs, and prescribing decision support. For opioids and controlled analgesics, machine learning models are increasingly used to identify patterns associated with misuse, diversion, high-risk prescribing, duplicate therapy, and drug interactions, supporting safer pain management when governed by validated data, transparent algorithms, human oversight, and strong privacy controls.

Key Regional Insights for Analgesics

Asia-Pacific is expanding in strategic importance due to aging populations, higher diagnosis of chronic pain conditions, broader healthcare access, and strong generic manufacturing capacity in China and India. Japan and South Korea support demand through advanced pain clinics, high life expectancy, and established reimbursement systems, while Australia maintains stringent medicine scheduling and safety communications through national regulators. Across Southeast Asia, pharmacy modernization and essential-medicine policies continue to improve access to affordable analgesics.

North America remains a highly mature analgesics environment shaped by established OTC consumption, advanced specialty pain care, and strict opioid stewardship. The United States continues to be influenced by CDC opioid prescribing guidance, FDA risk evaluation and mitigation strategies, prescription drug monitoring programs, and a strong movement toward non-opioid and multimodal approaches, while Canada emphasizes prescription monitoring, harm-reduction policies, and access to evidence-based pain care.

Latin America shows growing demand for affordable analgesics, particularly in Brazil and Mexico, but performance is influenced by healthcare access gaps, currency volatility, informal out-of-pocket spending, and public-sector procurement dynamics. Europe is characterized by robust pharmacovigilance, reimbursement discipline, and regulatory oversight under national agencies and the European Medicines Agency, with Germany, France, Italy, Spain, and the United Kingdom emphasizing safe opioid use, generic penetration, and clinical guideline alignment.

The Middle East, especially GCC countries, is investing in hospital capacity, specialty care, regulated pharmacy channels, and e-prescribing infrastructure, which supports more formalized pain management pathways. Africa continues to face significant unmet need for pain relief and palliative care due to access, affordability, supply continuity, and controlled-medicine availability constraints documented by global health agencies, making essential analgesic availability a persistent public health priority.

Key Group Insights for Analgesics

Within ASEAN, analgesics adoption is supported by expanding urban healthcare access, pharmacy modernization, rising OTC utilization, and regulatory harmonization efforts that improve product quality and cross-border market entry. The GCC benefits from high healthcare investment, hospital expansion, centralized procurement, and digital health programs, creating opportunities for branded, specialty, and hospital-administered analgesics under increasingly structured regulatory oversight.

The European Union remains a quality- and safety-driven environment where pharmacovigilance, centralized and national regulatory procedures, health technology assessment, and pricing discipline influence analgesic adoption. BRICS economies are important because Brazil, Russia, India, China, and South Africa combine large patient pools with domestic manufacturing capabilities, pricing controls, essential-medicine policies, and public health priorities that favor affordable generics and reliable supply.

G7 markets lead in clinical guidelines, safety monitoring, innovation funding, regulatory science, and real-world evidence generation, making them pivotal for non-opioid analgesic development and responsible post-market surveillance. NATO member countries add a distinct demand dimension through military medicine, trauma care, rehabilitation, emergency preparedness, and supply resilience planning for essential pain management therapies used in civilian and defense healthcare systems.

Key Country Insights for Analgesics

The United States is defined by high analgesic utilization, active opioid risk controls, prescription drug monitoring, and strong demand for non-opioid alternatives. Canada follows similar safety priorities with provincial reimbursement dynamics and monitoring programs, while Mexico combines OTC growth with affordability-driven generic demand and expanding pharmacy access. Brazil supports analgesics through private pharmacy networks, public procurement, essential-medicine policies, and strong generic uptake across a large and diverse healthcare system.

In Europe, the United Kingdom emphasizes clinical guidance, cost-effective prescribing, and opioid stewardship, while Germany benefits from advanced reimbursement structures, strong pharmacy access, and established pharmacovigilance. France maintains strict medicine oversight and public reimbursement, Italy and Spain show consistent demand tied to aging populations and musculoskeletal conditions, and Russia remains a large market shaped by domestic production priorities, controlled pricing policies, and changing import dynamics.

China and India are central to access and global supply, with China expanding healthcare coverage, hospital capacity, and domestic innovation while India maintains a major role in generic active pharmaceutical ingredients and finished dosage forms. Japan has sustained analgesic demand from a super-aged population and advanced clinical pathways, Australia emphasizes strict scheduling, poison information, and consumer safety, and South Korea combines advanced healthcare infrastructure with rapid uptake of differentiated pain management products and digital health tools.

Actionable Recommendations for Analgesics Leaders

Industry leaders should prioritize non-opioid innovation, safety-focused lifecycle management, and evidence generation that demonstrates clinically meaningful pain relief, lower adverse-event burden, and improved patient adherence. Investment in topical, extended-release, abuse-deterrent, pediatric-appropriate, geriatric-friendly, and combination formulations can help manufacturers differentiate in crowded generic and OTC segments.

Organizations should strengthen pharmacovigilance, real-world evidence capabilities, and regulatory intelligence to respond quickly to safety signals, label changes, scheduling decisions, and reimbursement expectations. Commercial teams should tailor strategies by channel, with medical education for prescription analgesics, consumer trust-building for OTC brands, responsible claims management, and digital pharmacy partnerships where regulation permits.

Supply resilience is also critical. Leaders should diversify API sourcing, qualify multiple manufacturing sites, monitor controlled-substance compliance, strengthen serialization and anti-counterfeit controls, and maintain transparent quality systems to reduce disruption risk in essential pain medicines.

Research Methodology for Analgesics Analysis

This executive summary is based on a structured research methodology that combines secondary research, primary industry validation, and analytical triangulation. Sources include public health agencies, regulatory authorities, clinical guidelines, pharmacovigilance communications, peer-reviewed literature, trade data, essential-medicine lists, reimbursement references, and recognized healthcare databases.

The analysis evaluates analgesics by product class, route of administration, prescription status, end user, distribution channel, region, economic bloc, and priority country. Findings are validated through cross-source comparison and interpreted using market drivers, restraints, regulatory shifts, supply chain indicators, safety signals, and demand-side healthcare trends to ensure data-backed and decision-ready insight while avoiding unsupported estimates, sizing, share, or forecasting claims.

Conclusion: The Future of Analgesics

The analgesics market is essential, resilient, and increasingly shaped by safety, access, and innovation. While OTC demand and generic availability support broad patient reach, opioid stewardship, NSAID safety concerns, and acetaminophen toxicity risks require disciplined product management, responsible promotion, and transparent communication.

Future leadership will favor organizations that combine clinically differentiated pain relief with strong compliance, responsible commercialization, AI-enabled evidence generation, and region-specific access strategies. As healthcare systems continue moving toward multimodal and personalized pain management, analgesics manufacturers that align efficacy, safety, affordability, and supply reliability will be best positioned to meet patient and provider needs.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Analgesics Market, by Type of Drug
7.1. Introduction
7.2. Non-Opioids
7.2.1. Acetaminophen
7.2.2. Non-Steroidal Anti-Inflammatory Drugs
7.2.3. Salicylates
7.3. Opioids
7.3.1. Codeine
7.3.2. Fentanyl
7.3.3. Hydrocodone
7.3.4. Morphine
7.3.5. Oxycodone
8. Analgesics Market, by Route of Administration
8.1. Introduction
8.2. Intramuscular
8.3. Intravenous (IV)
8.4. Oral
8.4.1. Capsules
8.4.2. Tablets
8.5. Rectal
8.6. Topical
8.7. Transdermal
9. Analgesics Market, by Prescription Status
9.1. Introduction
9.2. Over-The-Counter
9.3. Prescription
10. Analgesics Market, by Age Group
10.1. Introduction
10.2. Pediatric
10.3. Adult
10.4. Geriatric
11. Analgesics Market, by Indication
11.1. Introduction
11.2. Acute Pain
11.2.1. Injury-related pain
11.2.2. Postoperative pain
11.3. Chronic Pain
11.3.1. Arthritis
11.3.2. Back pain
11.3.3. Cancer pain
11.3.4. Neuropathic pain
12. Analgesics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Analgesics Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Analgesics Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Analgesics Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. AbbVie Inc.
17.3. Alembic Pharmaceuticals Ltd.
17.4. Amneal Pharmaceuticals LLC
17.5. Apotex Inc.
17.6. Assertio Holdings, Inc.
17.7. AstraZeneca PLC
17.8. Averitas Pharma, Inc.
17.9. Bausch Health Companies Inc.
17.10. Bayer AG
17.11. Bristol-Myers Squibb Company
17.12. C.H. Boehringer Sohn AG & Co. KG
17.13. Cipla Limited
17.14. Collegium Pharmaceutical, Inc.
17.15. CSPC Pharmaceutical Group
17.16. Dr. Reddy’s Laboratories Ltd.
17.17. Eli Lilly and Company
17.18. Endo International plc
17.19. F. Hoffmann-La Roche Ltd.
17.20. GlaxoSmithKline plc
17.21. Grünenthal GmbH
17.22. Haleon plc
17.23. Heron Therapeutics, Inc.
17.24. Hikma Pharmaceuticals plc
17.25. Johnson & Johnson Services, Inc.
17.26. Lupin Limited
17.27. Mallinckrodt plc
17.28. Merck KGaA
17.29. Novartis AG
17.30. Pacira BioSciences, Inc.
17.31. Perrigo Company plc
17.32. Pfizer Inc.
17.33. Sanofi S.A.
17.34. Sun Pharmaceutical Industries Limited
17.35. Teva Pharmaceutical Industries Ltd.
17.36. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL ANALGESICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANALGESICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANALGESICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANALGESICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANALGESICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANALGESICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ANALGESICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANALGESICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ANALGESICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ANALGESICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NON-OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NON-OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NON-OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ACETAMINOPHEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ACETAMINOPHEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ACETAMINOPHEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SALICYLATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SALICYLATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SALICYLATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CODEINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL FENTANYL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL FENTANYL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL FENTANYL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL HYDROCODONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL HYDROCODONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL HYDROCODONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MORPHINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MORPHINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MORPHINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL OXYCODONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL OXYCODONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL OXYCODONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL RECTAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ACUTE PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ACUTE PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ACUTE PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL INJURY-RELATED PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL INJURY-RELATED PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL INJURY-RELATED PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL POSTOPERATIVE PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL POSTOPERATIVE PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL POSTOPERATIVE PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CHRONIC PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL CHRONIC PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CHRONIC PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL BACK PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL BACK PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL BACK PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL CANCER PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL CANCER PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL CANCER PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 124. EUROPE ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. EUROPE ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 126. EUROPE ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 127. EUROPE ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 128. EUROPE ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. EUROPE ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 130. EUROPE ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 131. EUROPE ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 132. EUROPE ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 133. EUROPE ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 134. EUROPE ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 135. EUROPE ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. AFRICA ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 161. AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 162. AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 163. AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 164. AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 165. AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 166. AFRICA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 167. AFRICA ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 168. AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 169. AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 170. AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 171. AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 184. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. NATO ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. NATO ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 187. NATO ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 188. NATO ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 189. NATO ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 190. NATO ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 191. NATO ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 192. NATO ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 193. NATO ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 194. NATO ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 195. NATO ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 196. NATO ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. G7 ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. G7 ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 199. G7 ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 200. G7 ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 201. G7 ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 202. G7 ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 203. G7 ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 204. G7 ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 205. G7 ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 206. G7 ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 207. G7 ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 208. G7 ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. BRICS ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 210. BRICS ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 211. BRICS ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 212. BRICS ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 213. BRICS ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 214. BRICS ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 215. BRICS ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 216. BRICS ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 217. BRICS ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 218. BRICS ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 219. BRICS ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 220. BRICS ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. ASEAN ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 234. ASEAN ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 235. ASEAN ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 236. ASEAN ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 237. ASEAN ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. ASEAN ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 239. ASEAN ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 240. ASEAN ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 241. ASEAN ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 242. ASEAN ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 243. ASEAN ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 244. ASEAN ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. GCC ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 246. GCC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 247. GCC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 248. GCC ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 249. GCC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 250. GCC ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 251. GCC ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 252. GCC ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 253. GCC ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 254. GCC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 255. GCC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 256. GCC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 257. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 258. CHINA ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 259. CHINA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 260. CHINA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 261. CHINA ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 262. CHINA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. CHINA ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 264. CHINA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 265. CHINA ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 266. CHINA ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 267. CHINA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 268. CHINA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 269. CHINA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. UNITED STATES ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 282. JAPAN ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. JAPAN ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 284. JAPAN ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 285. JAPAN ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 286. JAPAN ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. JAPAN ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 288. JAPAN ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 289. JAPAN ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 290. JAPAN ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 291. JAPAN ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 292. JAPAN ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 293. JAPAN ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 294. INDIA ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. INDIA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 296. INDIA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 297. INDIA ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 298. INDIA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 299. INDIA ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 300. INDIA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 301. INDIA ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 302. INDIA ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 303. INDIA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 304. INDIA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 305. INDIA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 306. GERMANY ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. GERMANY ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 308. GERMANY ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 309. GERMANY ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 310. GERMANY ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 311. GERMANY ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 312. GERMANY ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 313. GERMANY ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 314. GERMANY ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 315. GERMANY ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 316. GERMANY ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 317. GERMANY ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 319. UNITED KINGDOM ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 326. UNITED KINGDOM ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 327. UNITED KINGDOM ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 328. UNITED KINGDOM ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 329. UNITED KINGDOM ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 330. AUSTRALIA ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 331. AUSTRALIA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 332. AUSTRALIA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 333. AUSTRALIA ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 334. AUSTRALIA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 335. AUSTRALIA ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 338. AUSTRALIA ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 339. AUSTRALIA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 340. AUSTRALIA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 341. AUSTRALIA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 342. FRANCE ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 343. FRANCE ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 344. FRANCE ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 345. FRANCE ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 346. FRANCE ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 347. FRANCE ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 348. FRANCE ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 349. FRANCE ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 350. FRANCE ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 351. FRANCE ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 352. FRANCE ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 353. FRANCE ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 354. SOUTH KOREA ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 355. SOUTH KOREA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 356. SOUTH KOREA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 357. SOUTH KOREA ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 358. SOUTH KOREA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 359. SOUTH KOREA ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 360. SOUTH KOREA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 361. SOUTH KOREA ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 362. SOUTH KOREA ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 363. SOUTH KOREA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 364. SOUTH KOREA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 365. SOUTH KOREA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 366. ITALY ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 367. ITALY ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 368. ITALY ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 369. ITALY ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 370. ITALY ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 371. ITALY ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 372. ITALY ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 373. ITALY ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 374. ITALY ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 375. ITALY ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 376. ITALY ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 377. ITALY ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 378. CANADA ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 379. CANADA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 380. CANADA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 381. CANADA ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 382. CANADA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 383. CANADA ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 384. CANADA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 385. CANADA ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 386. CANADA ANALGESICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 387. CANADA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2017-2032 (USD MILLION)
TABLE 388. CANADA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2017-2032 (USD MILLION)
TABLE 389. CANADA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 390. RUSSIA ANALGESICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 391. RUSSIA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2017-2032 (USD MILLION)
TABLE 392. RUSSIA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2017-2032 (USD MILLION)
TABLE 393. RUSSIA ANALGESICS MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 394. RUSSIA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 395. RUSSIA ANALGESICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 396. RUSSIA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 397. RUSSIA ANALGESICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 398. RUSSIA ANALGESICS MARKET SIZE, BY IN

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Assertio Holdings, Inc.
  • AstraZeneca PLC
  • Averitas Pharma, Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • C.H. Boehringer Sohn AG & Co. KG
  • Cipla Limited
  • Collegium Pharmaceutical, Inc.
  • CSPC Pharmaceutical Group
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann‑La Roche Ltd.
  • GlaxoSmithKline plc
  • Grünenthal GmbH
  • Haleon plc
  • Heron Therapeutics, Inc.
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mallinckrodt plc
  • Merck KGaA
  • Novartis AG
  • Pacira BioSciences, Inc.
  • Perrigo Company plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 47.99 Billion
Forecasted Market Value ( USD ) by 2032 $ 71.82 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned36

Related Topics

Related Reports

North America Analgesics Market Size, Share, Trends and Forecast by Type, Drug Class, Route of Administration, Pain Type, Application, and Country, 2026-2034 - Product Image

North America Analgesics Market Size, Share, Trends and Forecast by Type, Drug Class, Route of Administration, Pain Type, Application, and Country, 2026-2034

  • Report
  • 150 Pages
  • North America
From
Analgesics - Global Strategic Business Report - Product Image

Analgesics - Global Strategic Business Report

  • Report
  • 482 Pages
  • Global
From
Cancer Pain Management Market - Global Forecast 2026-2032 - Product Image

Cancer Pain Management Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Butorphanol Market - Global Forecast 2026-2032 - Product Image

Butorphanol Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Pain Management Drugs - Global Strategic Business Report - Product Image

Pain Management Drugs - Global Strategic Business Report

  • Report
  • 326 Pages
  • Global
From

About the Analgesics Market

The Analgesics market is a sector of the pharmaceutical industry that focuses on the production and sale of drugs used to relieve pain. Analgesics are used to treat a variety of conditions, including headaches, muscle pain, arthritis, and post-operative pain. Common analgesics include non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and acetaminophen. Analgesics are available in a variety of forms, including tablets, capsules, liquids, and topical creams. Many analgesics are available over-the-counter, while others require a prescription. The analgesics market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the analgesics market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Merck. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.